John Gay: Jennifer, good morning. I’ll take the first part of that–the second part of your question and then maybe ask John Donofrio to weigh in. But as it relates to guidance, we continue to evaluate that. Keep in mind, it’s been roughly nine months from a fiscal period that we’ve shown consolidated results, so I think we’re still working through that both internally and with the board on how to approach potential guidance going forward. That being said, as it relates to product or TRx growth and prescription growth, we continue to focus on that. Maybe John, you have some comments on that going forward?
John Donofrio: Yes, I think as you can tell, Jennifer, just the momentum we’ve had throughout the years across our products, we’ve had a few ups and downs in the psoriasis space, but we continue to be the market leader and expand persistent facial erythema, and we expect to continue to do that, that’s what our goal and our objectives are for 2023. I think the Paula and John’s point, the continued investment around that, we’ve demonstrated that that will also be dependent on funds going forward, but we expect to still grow that market and still seeing significant opportunity in the oral antibiotic market with MinoLira. Again, we feel like we’ve leveled out with the noise with the new–the competitors in the topical psoriasis market and we expect to see a rebound in that.
Again, we’re not giving guidance per se, but our brand plans, our tactics, we talked about SB206 and berdazimer plans, we have plans for all three products. They’ve all been initiated in a national sales meeting in early March and are being active, so we would expect to continue that momentum that we’ve seen.
Jennifer Kim: All right, thanks for taking my questions, guys.
Paula Brown Stafford: Thank you Jennifer.
John Gay: Thanks Jennifer.
Operator: Thank you. The next question comes from Kemp Dolliver with Brookline Capital Markets.
Kemp Dolliver: Thank you and good morning. This is based on backing into the numbers and could be off, but Wynzora fees look like they are down sequentially, or just in broad terms barely depressed versus last year’s quarters. Could you talk, A, is that correct, and then B, could you just discuss what’s going on behind that?
John Gay : Yes, so good morning Kemp, this is John. Thanks for your question. The Wynzora piece, keep in mind a couple of things. One, subsequent to the acquisition, the accounting presentation and treatment of Wynzora did evolve a little bit over time, so if you’re looking period over period, there could be some artificial changes. But effectively, the agreement with Wynzora, the way that it works is that–the agreement is that we’re the distributor and commercial partner for MC2 and for that product, so we effectively recognize all the revenue because we get the cash as it relates to the product sales, but we do effectively remit 85%, if you will, back to MC2 because effectively–and we share that as a COGS because effectively that’s the way that this agreement works.
The net-net, if you will, is the residual 15%. As it relates to changes in the fees, quote-unquote, or the part of the MC2 agreement that goes through COGS, that can vary based upon Wynzora and net product revenue, but then again, like I said, we’ve also had some presentation changes during the quarter–or I’m sorry, during the year, I should say.
Kemp Dolliver: Okay, but looking at the underlying script trend, is still a reliable measure of what the fees would be on a normalized basis?
